Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Stock Information for Atrium Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Atrium Therapeutics Inc.

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces $50 Million Private Placement
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.